Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Breast Neoplasms 64Neoplasms 8Sarcoma 6Ovarian Neoplasms 6Squamous Cell Carcinoma of Head and Neck 5Neoplasm Metastasis 5Sarcoma, Ewing 4Multiple Myeloma 4Lymphoma, Non-Hodgkin 4Glioma 4Carcinoma, Non-Small-Cell Lung 4Rhabdomyosarcoma 3Rhabdoid Tumor 3Prostatic Neoplasms 3Osteosarcoma 3Neuroblastoma 3Melanoma 3Medulloblastoma 3Lymphoma 3Liposarcoma 3Endometrial Neoplasms 3Colorectal Neoplasms 3Colonic Neoplasms 3Carcinoma, Renal Cell 3Wilms Tumor 2Rectal Neoplasms 2Pancreatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Lung Neoplasms 2Kidney Neoplasms 2

Interventions

durvalumab 5Nivolumab 3Cyclophosphamide 3Cisplatin 3130-nm albumin-bound paclitaxel 3padeliporfin 2anlotinib 2Trabectedin 2Sunitinib 2Pemetrexed 2Docetaxel 2Chemoradiotherapy 2Carboplatin 2Bevacizumab 2sotorasib 1relatlimab 1relacorilant 1pembrolizumab 1patritumab 1palbociclib 1olaparib 1niraparib 1nintedanib 1montanide ISA 51 1golotimod 1genexol-PM 1ceralasertib 1cemiplimab 1camrelizumab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neoplasms by Site × palbociclib × Clear all
NCT05935748 2025-11-12

Ph2 Study NKT2152 With Palbociclib & Sasanlimab in Subjects With Advanced Clear Cell Renal Cell Carcinoma (ccRcc)

NiKang Therapeutics, Inc.

Phase 2 Terminated
18 enrolled
Genitourinary

Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Urogenital Neoplasms, Urologic Diseases, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡